זידוודין - Zidovudine

זידוודין - Zidovudine
התוויות	Indicated for the management of serious manifestations of human immunodeficiency virus infections in patients with acquired immune deficiency syndrome, or AIDS-related complex (ARC). Evidence of efficacy has been demonstrated in AIDS patients who have recovered from their first episode of pneumocystis carinii pneumonia within four months and ARC patients with multiple signs of HIV infection, including mucocutaneous candidiasis, weight loss (more than 10% or 14 pounds), lymphadenopathy and unexplained fever.Retrovir capsules are indicated for the management of certain patients with early human immunodeficiency virus (HIV) disease such as those with HIV-associated symptoms and/or other recognised prognostic markers of impending progression to advanced disease. Evidence of efficacy has only been demonstrated in patients with T-4 (T-helper) cell counts of less than 500/mm3. 06/06/2011 בקשה לתוספת התויה : Update of dosage and administration

חומרים פעילים
קומביויר	LAMIVUDINE	150MG	ZIDOVUDINE	300MG }}

זידוודין - Zidovudine
שמות מסחריים	®RETROVIR


קבוצה פרמקולוגית (ATC)	"NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS"
שם גנרי	"זידוודין" (קישור לדף התרופה במאגר משרד הבריאות)
סל הבריאות	כלול
מסגרת הכללה בסל	תרופה מוגבלת לרישום ע"י רופא מומחה או הגבלה אחרת.
התוויות	Indicated for the management of serious manifestations of human immunodeficiency virus infections in patients with acquired immune deficiency syndrome, or AIDS-related complex (ARC). Evidence of efficacy has been demonstrated in AIDS patients who have recovered from their first episode of pneumocystis carinii pneumonia within four months and ARC patients with multiple signs of HIV infection, including mucocutaneous candidiasis, weight loss (more than 10% or 14 pounds), lymphadenopathy and unexplained fever.Retrovir capsules are indicated for the management of certain patients with early human immunodeficiency virus (HIV) disease such as those with HIV-associated symptoms and/or other recognised prognostic markers of impending progression to advanced disease. Evidence of efficacy has only been demonstrated in patients with T-4 (T-helper) cell counts of less than 500/mm3. 06/06/2011 בקשה לתוספת התויה : Update of dosage and administration
קיים גם בתכשירים	®COMBIVIR® ; TRIZIVIR